Schneider et al. [49] and Rafeeq et al. [46]as well as our review, likely emphasized the transformative impact of CFTR modulators on the treatment landscape of CF, which represents a significant shift from symptomatic treatment to targeting the underlying cause of the disease. The gene discussed is CFTR; the disease is cystic fibrosis.